ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0530

Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial

Carlijn Wagenaar1, Wendy Walrabenstein2, Marike van der Leeden2, Franktien Turkstra2, Jos Twisk3, Maarten Boers3, Henriët van Middendorp4, Peter Weijs5 and Dirkjan van Schaardenburg6, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, 3Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 4Leiden University, Leiden, Netherlands, 5Amsterdam University of Applied Sciences, Amsterdam, Netherlands, 6Amsterdam UMC, Amsterdam, Netherlands

Meeting: ACR Convergence 2024

Keywords: diet, health behaviors, nutrition, physical activity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease Activity Score (DAS28) compared to usual care in people with rheumatoid arthritis (RA).1,2 The aim of this study was to determine the long-term effectiveness of the PFJ lifestyle intervention on disease activity in people with RA two years after the PFJ intervention. 

Methods: In the PFJ assessor-blind randomized clinical trial (RCT), people with RA (DAS28 ≥ 2.6 and ≤ 5.1) were randomized to receive the PFJ intervention in addition to usual care, or the control group which received usual care. After this 16-week RCT period the control group also received the intervention. After completion of the intervention participants were followed up for two years with biannual visits and six adherence-promoting webinars per year. Participants with a DAS28 < 2.6 received a protocol as a suggested approach to taper antirheumatic medication with their rheumatologist. Changes in medication intensity between trial initiation and end of the extension study were classified as “increase”, “stable”, or “decrease” by an independent committee. Secondary outcomes included anthropometric and metabolic markers. An intention-to-treat analysis with a linear mixed model was used to analyze changes over time.

Results: 48 (62%) of the 77 trial completers also completed the two-year follow-up. Overall, 92% of participants were female with a mean (SD) age of 55 (12) and baseline body mass index of 26 (4) kg/m². Two years after completing the PFJ intervention the improvement in DAS28 after PFJ was maintained, and significantly lower compared to baseline: mean –0.9 (95% CI –1.2, –0.6; p < 0.0001; Figure 1). Tender joint count and general health components of the DAS28 improved significantly, while there was no significant difference in the (already low) erythrocyte sedimentation rate and swollen joint count compared to baseline (Table 1). Results were similar in participants completing the two-year extension study vs. those that discontinued prematurely: mean DAS28 change during intervention completer: –0.9, dropout: –0.6; p = 0.4; mean change up to first year extension study completer: –1.0, dropout: –0.9; p = 0.9. Of the 39 participants who completed the follow-up and used disease modifying anti-rheumatic medication, 17 (44%) decreased or stopped, 10 (26%) had stable, and 12 (31%) had increased medication. 30 participants (65%) had improved DAS28 scores (11 with DAS28 < 2.6) with stable or less medication compared to baseline. After the two-year follow-up period HDL cholesterol was increased and CRP remained significantly lower compared to baseline values, although there was no longer a significant difference in weight, waist circumference, LDL cholesterol, or HbA1c.

Conclusion: Significant improvements in disease activity observed after the PFJ intervention were maintained up to two years, while, on average, medication was slightly reduced. These findings indicate that intensive lifestyle modifications can be effective in the long term.

References:

  1. Walrabenstein, Trials 2021
  2. Walrabenstein, Rheumatology 2023

Supporting image 1

Figure 1. Mean change in DAS28 (a) per original trial arm and (b) for the whole cohort (all participants, data combined at start of active PFJ program). PFJ = Plants for Joints lifestyle program. Error bars represent 95% confidence interval (horizontal) and standard deviation (vertical).

Supporting image 2

Table 1. Plants for Joints cohort at start and end of the 16-week intervention period as well as during the two year extension study (12 and 24 months after completing the intervention). Continuous variables reported as mean (SD) when normally distributed or as median [IQR] when skewed. Within-group difference shown between start of the lifestyle intervention and end of the 24-month follow-up determined using the linear-mixed model when model assumptions were met. For variables in which model assumptions were not met (†) a linear-mixed model was performed after log transformation and within group differences were reported as median difference of complete paired values determined using a Wilcoxon test (p-values from the linear mixed model are shown, all were similar to the Wilcoxon test). ESR = Erythrocyte sedimentation rate.


Disclosures: C. Wagenaar: Plants for Health B.V., 4; W. Walrabenstein: Plants for Health B.V., 4; M. van der Leeden: None; F. Turkstra: None; J. Twisk: None; M. Boers: None; H. van Middendorp: None; P. Weijs: None; D. van Schaardenburg: Plants for Health B.V., 11.

To cite this abstract in AMA style:

Wagenaar C, Walrabenstein W, van der Leeden M, Turkstra F, Twisk J, Boers M, van Middendorp H, Weijs P, van Schaardenburg D. Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/long-term-effectiveness-of-a-lifestyle-intervention-for-rheumatoid-arthritis-two-year-follow-up-after-the-plants-for-joints-randomized-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-effectiveness-of-a-lifestyle-intervention-for-rheumatoid-arthritis-two-year-follow-up-after-the-plants-for-joints-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology